Here’s What Fueled These 10 Firms’ Surge

3. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers rallied for a fourth consecutive day on Tuesday, jumping 18.12 percent to end at $49.47 each, as investor sentiment was fueled by its impressive earnings performance in the first quarter of the year and announcements that more collaborations are expected.

In its financial statement, Hims & Hers Health, Inc. (NYSE:HIMS) said net income expanded by 346 percent to $49.5 million from the $11.1 million registered in the same period last year. Revenues soared by 111 percent to $586 million from $278.2 million year-on-year.

According to the company, the strong performance underpinned its updated 2025 guidance, with full-year revenues expected to settle between $2.3 billion and $2.4 billion, and between $530 million and $550 million for the second quarter.

In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.

With the partnership, Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.